Our NIOX® FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. We provide the latest generation NIOX VERO® directly to healthcare professionals through our teams in the US, China, Germany, UK, and in a wide range of further countries through our international network of distribution partners.
NIOX® is a FeNO pioneer and market-leader and we are dedicated to maintaining our position as the ‘gold standard’ provider, helping healthcare professionals offer the best asthma care worldwide. With our development scientists focused on next generation NIOX® innovations, our dedicated supply teams maintaining production and delivery of devices, consumables and tests, and our commercial teams providing quality customer support, we are fully focused on being the number one FeNO partner.
For more information including full prescribing information please visit our dedicated NIOX® website
Asthma and airway inflammation
Asthma is a common lung disease affecting nearly 340 million people worldwide and is the world’s most common chronic disease among children.1 Its major underlying cause is airway inflammation, which can be irritated by external triggers, such as allergens, tobacco smoke, cold air, chest infections and certain chemicals. This can cause airway constriction and mucus secretion, which can make breathing more difficult and result in symptoms such as coughing, wheezing and breathlessness. Asthma exacerbations occur when the number and / or level of symptoms increase and become more intense. Severe asthma exacerbations can require emergency care, and may even be fatal.
Monitoring airway inflammation – monitoring asthma
NIOX® exploits the discovery that the majority of patients with allergic airway inflammation have higher levels of nitric oxide in their exhaled breath. By measuring the concentration of this gas (the fractional exhaled nitric oxide or FeNO), clinicians can evaluate the underlying inflammation.
NIOX VERO® is a non-invasive, simple-to-use, point-of-care system that provides rapid standardized FeNO measurements. With over 38 million NIOX® tests undertaken to date, our system is used by healthcare professionals around the world to help improve asthma care, assisting:
- determining responsiveness to inhaled corticosteroids
- tailoring inhaled steroid use
- monitoring treatment compliance
- reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring
For more information including full prescribing information please visit our dedicated NIOX® website.
Important Safety Information Regarding NIOX VERO® (United States)
NIOX VERO® is a portable system for the non-invasive, quantitative, simple and safe measurement of Nitric Oxide (NO) in human breath. Nitric Oxide is frequently increased in some inflammatory processes such as asthma. Measuring the fractional NO concentration in expired breath (FeNO) provides the physician with means of evaluating an asthma patient’s response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma. NIOX VERO is intended for prescription use and should only be used as directed in the NIOX VERO User Manual by trained healthcare professionals. NIOX VERO is suitable for children, 7–17 years, and adults 18 years and older. NIOX VERO can be operated in two exhalation modes, 10 seconds or 6 seconds. The 10-second test mode is for age 7 and up. The 6-second test mode is for ages 7–10 only when a 10-second test is not successful. NIOX VERO cannot be used with infants or by children under the age of 7, as measurement requires patient cooperation. NIOX VERO should not be used in critical care, emergency care or in anesthesiology.
NIOX VERO® and NIOX® are registered trademarks of Circassia AB.
1 – Asthma Q and A – World Health Organisation – https://www.who.int/news-room/q-a-detail/asthma